A Cryptochrome 2 Mutation Yields Advanced Sleep Phase in Human

  1. Arisa Hirano
  2. Guangsen Shi
  3. Christopher R Jones
  4. Anna Lipzen
  5. Len A Pennacchio
  6. Ying Xu
  7. William C Hallows
  8. Thomas McMahon
  9. Maya Yamazaki
  10. Louis J Ptáček  Is a corresponding author
  11. Ying-Hui Fu  Is a corresponding author
  1. University of California San Francisco, United States
  2. University of California, San Francisco, United States
  3. University of Utah, United States
  4. Lawrence Berkeley National Laboratory, United States
  5. Soochow University, China

Abstract

Familial Advanced Sleep Phase (FASP) is a heritable human sleep phenotype characterized by very early sleep and wake times. We identified a missense mutation in the human Cryptochrome 2 (CRY2) gene that co-segregates with FASP in one family. The mutation leads to replacement of an alanine residue at position 260 with a threonine (A260T). In mice, the CRY2 mutation causes a shortened circadian period and reduced phase-shift to early-night light pulse associated with phase-advanced behavioral rhythms in the light-dark cycle. The A260T mutation is located in the phosphate loop of the flavin adenine dinucleotide (FAD) binding domain of CRY2. The mutation alters the conformation of CRY2, increasing its accessibility and affinity for FBXL3 (an E3 ubiquitin ligase), thus promoting its degradation. These results demonstrate that CRY2 stability controlled by FBXL3 plays a key role in the regulation of human sleep wake behavior.

Article and author information

Author details

  1. Arisa Hirano

    Department of Neurology, University of California San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  2. Guangsen Shi

    Department of Neurology, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  3. Christopher R Jones

    Department of Neurology, University of Utah, Salt Lake City, United States
    Competing interests
    No competing interests declared.
  4. Anna Lipzen

    Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Walnut Creek, United States
    Competing interests
    No competing interests declared.
  5. Len A Pennacchio

    DOE Joint Genome Institute, Lawrence Berkeley National Laboratory, Walnut Creek, United States
    Competing interests
    No competing interests declared.
  6. Ying Xu

    Center for System Biology, Soochow University, Suzhou, China
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6689-7768
  7. William C Hallows

    Department of Neurology, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8306-8438
  8. Thomas McMahon

    Department of Neurology, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  9. Maya Yamazaki

    Department of Neurology, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  10. Louis J Ptáček

    Department of Neurology, University of California, San Francisco, San Francisco, United States
    For correspondence
    ljp@ucsf.edu
    Competing interests
    Louis J Ptáček, Reviewing editor, eLife.
  11. Ying-Hui Fu

    Department of Neurology, University of California, San Francisco, San Francisco, United States
    For correspondence
    ying-hui.fu@ucsf.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6628-0266

Funding

National Heart, Lung, and Blood Institute (HL059596)

  • Louis J Ptáček

National Institute of General Medical Sciences (GM079180)

  • Ying-Hui Fu

Japan Society for the Promotion of Science

  • Arisa Hirano

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All experimental protocols (Protocol no. AN111686-02) were conducted according to US National Institutes of Health guidelines for animal research andwere approved by the Institutional Animal Care and Use Committee at the University of California, San Francisco.

Human subjects: All human subjects signed a consent form approved by the Institutional Review Boards at the University of Utah and the University of California, San Francisco (IRB# 10-03952). The consent form includes all confidentiality and ethic guidelines and also indicates not revealing subject information in the publication.

Copyright

© 2016, Hirano et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,132
    views
  • 834
    downloads
  • 117
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Arisa Hirano
  2. Guangsen Shi
  3. Christopher R Jones
  4. Anna Lipzen
  5. Len A Pennacchio
  6. Ying Xu
  7. William C Hallows
  8. Thomas McMahon
  9. Maya Yamazaki
  10. Louis J Ptáček
  11. Ying-Hui Fu
(2016)
A Cryptochrome 2 Mutation Yields Advanced Sleep Phase in Human
eLife 5:e16695.
https://doi.org/10.7554/eLife.16695

Share this article

https://doi.org/10.7554/eLife.16695

Further reading

    1. Neuroscience
    Benjamin R Kop, Yazan Shamli Oghli ... Lennart Verhagen
    Research Advance

    Transcranial ultrasonic stimulation (TUS) is rapidly emerging as a promising non-invasive neuromodulation technique. TUS is already well-established in animal models, providing foundations to now optimize neuromodulatory efficacy for human applications. Across multiple studies, one promising protocol, pulsed at 1000 Hz, has consistently resulted in motor cortical inhibition in humans (Fomenko et al., 2020). At the same time, a parallel research line has highlighted the potentially confounding influence of peripheral auditory stimulation arising from TUS pulsing at audible frequencies. In this study, we disentangle direct neuromodulatory and indirect auditory contributions to motor inhibitory effects of TUS. To this end, we include tightly matched control conditions across four experiments, one preregistered, conducted independently at three institutions. We employed a combined transcranial ultrasonic and magnetic stimulation paradigm, where TMS-elicited motor-evoked potentials (MEPs) served as an index of corticospinal excitability. First, we replicated motor inhibitory effects of TUS but showed through both tight controls and manipulation of stimulation intensity, duration, and auditory masking conditions that this inhibition was driven by peripheral auditory stimulation, not direct neuromodulation. Furthermore, we consider neuromodulation beyond driving overall excitation/inhibition and show preliminary evidence of how TUS might interact with ongoing neural dynamics instead. Primarily, this study highlights the substantial shortcomings in accounting for the auditory confound in prior TUS-TMS work where only a flip-over sham and no active control was used. The field must critically reevaluate previous findings given the demonstrated impact of peripheral confounds. Furthermore, rigorous experimental design via (in)active control conditions is required to make substantiated claims in future TUS studies. Only when direct effects are disentangled from those driven by peripheral confounds can TUS fully realize its potential for research and clinical applications.

    1. Medicine
    2. Neuroscience
    Srdjan Sumarac, Kiah A Spencer ... Luka Milosevic
    Research Article

    Background:

    The dichotomy between the hypo- versus hyperkinetic nature of Parkinson’s disease (PD) and dystonia, respectively, is thought to be reflected in the underlying basal ganglia pathophysiology. In this study, we investigated differences in globus pallidus internus (GPi) neuronal activity, and short- and long-term plasticity of direct pathway projections.

    Methods:

    Using microelectrode recording data collected from the GPi during deep brain stimulation surgery, we compared neuronal spiketrain features between people with PD and those with dystonia, as well as correlated neuronal features with respective clinical scores. Additionally, we characterized and compared readouts of short- and long-term synaptic plasticity using measures of inhibitory evoked field potentials.

    Results:

    GPi neurons were slower, bustier, and less regular in dystonia. In PD, symptom severity positively correlated with the power of low-beta frequency spiketrain oscillations. In dystonia, symptom severity negatively correlated with firing rate and positively correlated with neuronal variability and the power of theta frequency spiketrain oscillations. Dystonia was moreover associated with less long-term plasticity and slower synaptic depression.

    Conclusions:

    We substantiated claims of hyper- versus hypofunctional GPi output in PD versus dystonia, and provided cellular-level validation of the pathological nature of theta and low-beta oscillations in respective disorders. Such circuit changes may be underlain by disease-related differences in plasticity of striato-pallidal synapses.

    Funding:

    This project was made possible with the financial support of Health Canada through the Canada Brain Research Fund, an innovative partnership between the Government of Canada (through Health Canada) and Brain Canada, and of the Azrieli Foundation (LM), as well as a grant from the Banting Research Foundation in partnership with the Dystonia Medical Research Foundation (LM).